← board
LIXT
distress 5/10 · elevated risk$4.99-8%today-38% from 52w high
Lead: ovarian clear cell carcinoma · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$3M
Runway
0.8 yrs
Shares 1y
+172%
Price & events
+49.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-7.8%
1D
-11.5%
1W
-33.3%
1M
+30.3%
3M
+49.0%
6M
+17.4%
1Y
—
2Y
—
5Y
+124.8%
All
Overview
- Market Cap
- $61.79M
- Volume
- 579.20K
- 52 Week Range
- $1.18 – $8.04
- Total Shares
- 12.38M
- Short %
- 2.24%
- % Held by Insiders
- 7.26%
- % Held by Institutions
- 4.87%
- RVOL
- 1.22x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 8
- 2026-07-01partnershipMerger with Nomad Transportable Power Systems consummatedSEC 8-K
- 2026-06-30partnershipAmendment to Merger Agreement executedSEC 8-K
- first half of 2026conferencedata presentationsecondaryLB-100 · Initial data from first 21 patients to be presented.SEC 8-K
- 2026-06-11partnershipDefinitive agreement to acquire NOMAD Transportable Power SystemsSEC 8-K
- 2026-06-11partnershipMerger Agreement entered into with NomadSEC 8-K
- second half of 2025readoutLB100 · First results of clinical studies with LB100 in combination with checkpoint immunotherapy.SEC 8-K
- 2025-12-17partnershipLB-100 · Expanded collaboration with MD Anderson and GSK to increase trial enrollment from 21 to 42 patients.SEC 8-K
- 2025-11-24partnershipAcquired all shares of Liora Technologies, gaining proton therapy assets (LIGHT system) via share exchange.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 12,382,944 · 0 offerings/1y · 0 PIPEs
- 2024-07-128-Kmaterial_agreement
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — ovarian clear cell carcinoma
Recent news
- 2026-07-14Lixte Biotechnology Holdings Inc. (LIXT) Q4 2024 Earnings: Net Loss Highlights Pre-Revenue Stage - Earnings Surprise Stocks - dars.gov.et
- 2026-07-06AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD - TradingView
- 2026-07-06LIXTE Completes Corporate Name Change to NOMAD Power - GlobeNewswire
- 2026-07-06News On Lixte Biotechnology Holdings Inc. (LIXT) Now Under NMAD - Moomoo
- 2026-07-06AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD - The Globe and Mail
- 2026-07-06LIXTE becomes NOMAD Power Solutions as Nasdaq ticker switches to NMAD - Stock Titan
- 2026-07-02Lixte (LIXT) director receives 15,000 RSUs equity grant - Stock Titan
- 2026-07-02Lixte Biotechnology (LIXT) director awarded 40,000 RSUs, now holds 65,000 - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.